Kyowa Kirin acquires Orchard Therapeutics for $477.6m
25 Jan 2024
AcquisitionGene TherapyPriority ReviewLicense out/inCell Therapy
Preview
Source: Pharmaceutical Technology
The deal will enhance Kyowa Kirin’s focus on addressing the unmet medical needs of individuals with genetic and other severe diseases. Credit: Mongkolchon Akesin/Shutterstock.com.
Preview
Source: Pharmaceutical Technology
Kyowa Kirin, a Japan-based global speciality pharmaceutical company, has announced the successful completion of its acquisition of Orchard Therapeutics, a developer of hematopoietic stem cell gene therapies, for an equity value of $477.6m (Y70.47bn).
Orchard becomes a fully owned Kyowa Kirin subsidiary.
The integration of Orchard into Kyowa Kirin’s operations will enhance the company’s focus on addressing the unmet medical needs of individuals with genetic and other severe diseases.
Orchard’s portfolio includes Libmeldy (atidarsagene autotemcel), a gene therapy approved in the EU and UK for early-onset MLD, a rare disease.
Libmeldy, also called OTL-200 in the US, is under priority review by the US Food and Drug Administration. A decision on its approval is anticipated on 18 March 2024, under the Prescription Drug User Fee Act.
Orchard is also advancing two other clinical-stage programmes using its hematopoietic stem cell gene therapy platform: OTL-203 for mucopolysaccharidosis type I Hurler’s syndrome and OTL-201 for mucopolysaccharidosis type IIIA.
The acquisition will enrich Kyowa Kirin’s portfolio, supporting the development of therapeutic candidates and facilitating the ongoing and future launches of Libmeldy in early-onset MLD.
Orchard co-founder and CEO Bobby Gaspar will join Kyowa Kirin’s senior research and development leadership team, reporting to president and CEO Masashi Miyamoto.
Orchard’s employees will continue their work from the company’s existing locations in London, UK, and Boston, US.
Miyamoto said: “We are truly excited about the acquisition of Orchard Therapeutics, a leading provider of HSC gene therapy.
“This platform offers significant potential to deliver more innovative treatments and breakthrough therapies and aligns with our purpose to deliver life-changing value for people living with rare and complex diseases.
“Going forward, our companies will build on the extensive experience of Orchard’s gene therapy platform and apply it to under-served indications and diseases where we believe it to be scientifically and clinically differentiated.”
In January 2024, Kyowa Kirin and Boehringer Ingelheim entered a licensing agreement to develop a new treatment for fibro-inflammatory diseases.
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
By Cytiva Thematic
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.